AKIN GUMP STRAUSS HAUER & FELD

Lobbying for UCB, INC. · Biopharmaceutical company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · Georgia · House · Senate · $80,000.00 income · posted Apr 20, 2026

Lobbying activity 1

Trade (domestic/foreign)

Issues related to global biopharmaceutical supply chain; Issues related to Section 232 investigations on pharmaceuticals.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.